Tsuchihara K - Search Results

1

Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities.

Sakai SA, Aoshima M, Sawada K, Horasawa S, Yoshikawa A, Fujisawa T, Kadowaki S, Denda T, Matsuhashi N, Yasui H, Goto M, Yamazaki K, Komatsu Y, Nakanishi R, Nakamura Y, Bando H, Hamaya Y, Kageyama SI, Yoshino T, Tsuchihara K, Yamashita R. Sakai SA, et al. Among authors: tsuchihara k. Front Cell Infect Microbiol. 2022 Sep 14;12:925444. doi: 10.3389/fcimb.2022.925444. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36189350 Free PMC article.

2

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H. Ogasawara N, et al. Among authors: tsuchihara k. Jpn J Clin Oncol. 2011 Jan;41(1):52-6. doi: 10.1093/jjco/hyq151. Epub 2010 Aug 9. Jpn J Clin Oncol. 2011. PMID: 20696815

3

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

Bando H, Tsuchihara K, Yoshino T, Kojima M, Ogasawara N, Fukushima H, Ochiai A, Ohtsu A, Esumi H. Bando H, et al. Among authors: tsuchihara k. Jpn J Clin Oncol. 2011 Feb;41(2):239-44. doi: 10.1093/jjco/hyq216. Epub 2010 Nov 26. Jpn J Clin Oncol. 2011. PMID: 21113056

4

KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab.

Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A. Bando H, et al. Among authors: tsuchihara k. Br J Cancer. 2011 Jul 26;105(3):403-6. doi: 10.1038/bjc.2011.247. Epub 2011 Jul 5. Br J Cancer. 2011. PMID: 21730978 Free PMC article.

5

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer.

Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M, Ochiai A, Bando H, Fuse N, Tahara M, Doi T, Esumi H, Komatsu Y, Ohtsu A. Kawamoto Y, et al. Among authors: tsuchihara k. Br J Cancer. 2012 Jul 10;107(2):340-4. doi: 10.1038/bjc.2012.218. Epub 2012 May 22. Br J Cancer. 2012. PMID: 22617127 Free PMC article.

6

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Bando H, et al. Among authors: tsuchihara k. Jpn J Clin Oncol. 2012 Dec;42(12):1146-51. doi: 10.1093/jjco/hys160. Epub 2012 Oct 15. Jpn J Clin Oncol. 2012. PMID: 23071293

7

Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.

Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Bando H, et al. Among authors: tsuchihara k. BMC Cancer. 2013 Sep 3;13:405. doi: 10.1186/1471-2407-13-405. BMC Cancer. 2013. PMID: 24006859 Free PMC article.

8

DBTSS as an integrative platform for transcriptome, epigenome and genome sequence variation data.

Suzuki A, Wakaguri H, Yamashita R, Kawano S, Tsuchihara K, Sugano S, Suzuki Y, Nakai K. Suzuki A, et al. Among authors: tsuchihara k. Nucleic Acids Res. 2015 Jan;43(Database issue):D87-91. doi: 10.1093/nar/gku1080. Epub 2014 Nov 5. Nucleic Acids Res. 2015. PMID: 25378318 Free PMC article.

9

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.

Taniguchi H, Yamazaki K, Yoshino T, Muro K, Yatabe Y, Watanabe T, Ebi H, Ochiai A, Baba E, Tsuchihara K; Japanese Society of Medical Oncology. Taniguchi H, et al. Among authors: tsuchihara k. Cancer Sci. 2015 Mar;106(3):324-7. doi: 10.1111/cas.12595. Cancer Sci. 2015. PMID: 25800101 Free PMC article.

10

Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.

Yoshino T, Uetake H, Tsuchihara K, Shitara K, Yamazaki K, Oki E, Sato T, Naitoh T, Komatsu Y, Kato T, Yamanaka K, Iwasaki K, Soeda J, Hihara M, Yamanaka T, Ochiai A, Muro K. Yoshino T, et al. Among authors: tsuchihara k. Clin Colorectal Cancer. 2017 Jun;16(2):158-163. doi: 10.1016/j.clcc.2017.01.001. Epub 2017 Jan 24. Clin Colorectal Cancer. 2017. PMID: 28237539 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page